Market-Moving News for June 13th
$CERO
$LGVN
$TSLA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/30/2026 | $150.00 → $145.00 | Underweight | Analyst | |
| 1/12/2026 | $120.00 → $130.00 | Underweight | Wells Fargo | |
| 1/2/2026 | $444.00 → $439.00 | Hold | Truist | |
| 12/8/2025 | $425.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 10/29/2025 | $341.00 → $471.00 | Neutral | BofA Securities | |
| 10/23/2025 | $450.00 → $485.00 | Outperform | Mizuho | |
| 10/23/2025 | $490.00 → $482.00 | Buy | Canaccord Genuity | |
| 10/23/2025 | $435.00 → $440.00 | Buy | Deutsche Bank |
4 - Tesla, Inc. (0001318605) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously
Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $130.00 from $120.00 previously
Truist reiterated coverage of Tesla with a rating of Hold and set a new price target of $439.00 from $444.00 previously
4 - Tesla, Inc. (0001318605) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron's laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationWith the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel's Biological License Application (BLA) is approved by the FDA before September 2029 MIAMI, Feb. 05
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a presentation highlighting data to date from the Company's Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company's recent clinical update, the data highlight results from the first cohort
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron's growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeveron's proprietary mesenchymal stem cell therapy, has delivered positive initial results across five clinical trials in three indications, including Hypoplastic Left Heart Syndrome, Alzheimer's disease and Aging-related Frailty MIAMI,
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity (DLT) observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion w
In the fourth quarter, we produced over 434,000 vehicles, delivered over 418,000 vehicles and deployed 14.2 GWh of energy storage products – a record for deployments. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q4 2025 Production Deliveries Subject to operating lease accounting Model 3/Y 422,652 406,585 3% Other Models 11,706 11,642 5% Total 434,358 418,227 3% 2025 Production Deliveries Model 3/Y 1,600,767 1,585,279 Other Models 53,900 50,850
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number: 1.877.407.0789Conference ID: 13755997 Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta
This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)